Anavex Life Sciences Corp - Company & Market Research Reports

Anavex Life Sciences is a biopharmaceutical company that develops differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, including drug candidates to treat diseases of the central nervous system, pain and various types of cancer. The company's best known product is ANAVEXTM 2-73, a compound being developed to treat Alzheimer's disease, Parkinson's disease and related diseases. The company was founded in 2006 and is based in New York.

Neuropathic Pain - Pipeline Review, H2 2017 - Product Thumbnail Image

Neuropathic Pain - Pipeline Review, H2 2017

  • Report
  • 488 Pages
From
Neuropathic Pain - Pipeline Review, H1 2017 - Product Thumbnail Image

Neuropathic Pain - Pipeline Review, H1 2017

  • Report
  • 485 Pages
From
Alzheimer's Disease - Pipeline Review, H1 2018 - Product Thumbnail Image

Alzheimer's Disease - Pipeline Review, H1 2018

  • Report
  • 1203 Pages
From
Prostate Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Prostate Cancer - Pipeline Review, H1 2018

  • Report
  • 2069 Pages
From
Pain Drug Development Pipeline Review, 2017 - Product Thumbnail Image

Pain Drug Development Pipeline Review, 2017

  • Report
  • 229 Pages
From
Depression - Pipeline Review, H1 2018 - Product Thumbnail Image

Depression - Pipeline Review, H1 2018

  • Report
  • 490 Pages
From
Infantile Spasms Therapeutics Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024 - Product Thumbnail Image

Infantile Spasms Therapeutics Market: Global Industry Analysis, Trends, Market Size and Forecasts up to 2024

  • Report
  • 100 Pages
From
Global Rett Syndrome Market: Industry Analysis & Outlook (2017-2025) - Product Thumbnail Image

Global Rett Syndrome Market: Industry Analysis & Outlook (2017-2025)

  • Drug Pipelines
  • 64 Pages
From
Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018 - Product Thumbnail Image

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018

  • Report
  • 487 Pages
From
Parkinson's Disease - Pipeline Review, H1 2018 - Product Thumbnail Image

Parkinson's Disease - Pipeline Review, H1 2018

  • Report
  • 881 Pages
From
Rett Syndrome - Pipeline Review, H1 2018 - Product Thumbnail Image

Rett Syndrome - Pipeline Review, H1 2018

  • Report
  • 114 Pages
From
Fragile X Syndrome - Pipeline Review, H1 2018 - Product Thumbnail Image

Fragile X Syndrome - Pipeline Review, H1 2018

  • Report
  • 133 Pages
From
Dementia - Pipeline Review, H1 2018 - Product Thumbnail Image

Dementia - Pipeline Review, H1 2018

  • Report
  • 260 Pages
From
Epilepsy - Pipeline Review, H1 2018 - Product Thumbnail Image

Epilepsy - Pipeline Review, H1 2018

  • Report
  • 418 Pages
From
Multiple Sclerosis - Pipeline Review, H2 2017 - Product Thumbnail Image

Multiple Sclerosis - Pipeline Review, H2 2017

  • Report
  • 780 Pages
From
Multiple Sclerosis - Pipeline Review, H1 2017 - Product Thumbnail Image

Multiple Sclerosis - Pipeline Review, H1 2017

  • Report
  • 812 Pages
From
Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016 - Product Thumbnail Image

Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016

  • Report
  • 63 Pages
From
Fragile X Syndrome - Pipeline Insight, 2018 - Product Thumbnail Image

Fragile X Syndrome - Pipeline Insight, 2018

  • Drug Pipelines
  • 50 Pages
From
Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016 - Product Thumbnail Image

Infantile Spasm (West Syndrome) - Pipeline Review, H1 2016

  • Report
  • 55 Pages
From
Pancreatic Cancer - Pipeline Review, H1 2018 - Product Thumbnail Image

Pancreatic Cancer - Pipeline Review, H1 2018

  • Report
  • 2509 Pages
From
Loading Indicator
adroll